STX107

DRUG3 trials

Sponsors

Seaside Therapeutics, Inc., National Institute of Mental Health (NIMH)

Conditions

Fragile X SyndromemGluR5 Receptors

Phase 1

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

CompletedNCT00965432

Seaside Therapeutics, Inc.Fragile X Syndrome

Start: 2009-09-30End: 2010-02-28Target: 40Updated: 2010-02-08

Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain

CompletedNCT01896843

National Institute of Mental Health (NIMH)mGluR5 Receptors

Start: 2013-06-27End: 2016-06-16Updated: 2018-09-27

Phase 2

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

SuspendedNCT01325740

Seaside Therapeutics, Inc.Fragile X Syndrome

Start: 2011-05-31End: 2013-09-30Target: 16Updated: 2012-12-20